Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)

Abstract

Background Since the outbreak of coronavirus disease 2019 (COVID-19), many researchers in China have performed related clinical research. However, systematic reviews of the registered clinical trials are still lacking. Therefore, we conducted a systematic review of clinical trials for COVID-19 to summarize their characteristics. Methods This study is based on the PRISMA recommendations in the Cochrane handbook. The Chinese Clinical Registration Center and the ClinicalTrials.gov databases were searched to identify registered clinical trials related to COVID-19. The retrieval inception date was February 9, 2020. Two researchers independently selected the literature based on the inclusion and exclusion criteria, extracted data, and evaluated the risk of bias. Results A total of 75 registered clinical trials (63 interventional studies and 12 observational studies) for COVID-19 were identified. The majority of clinical trials were sponsored by Chinese hospitals. Only 11 trials have begun to recruit patients, and none of the registered clinical trials have been completed; 34 trials were early clinical exploratory trials or in the pre-experiment stage, 13 trials were phase III, and four trials were phase IV. The intervention methods included traditional Chinese medicine in 26 trials, Western medicine in 30 trials, and integrated traditional Chinese medicine and Western medicine in 19 trials. The subjects were primarily non-critical adult patients (≥ 18 years old). The median sample size of the trials was 100 (IQR: 60–200), and the median length of the trial periods was 179 d (IQR: 94–366 d). The main outcomes were clinical observation and examinations. Overall, the methodological quality of both the interventional trials and observational studies was low. Conclusions Intensive clinical trials on the treatment of COVID-19 using traditional Chinese medicine and Western medicine are ongoing or will be performed in China. However, based on the uncertain methodological quality, small sample size, and long trial duration, we will not be able to obtain reliable, high-quality clinical evidence regarding the treatment of COVID-19 in the near future. Improving the quality of study design, prioritizing promising drugs, and using different designs and statistical methods are worth advocating and recommending for clinical trials of COVID-19 in the future.

A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules

“…The race to find a treatment of this deadly viral infectious disease has started all over the world [105] , [106] , [107] . More than one thousand trials of various synthetic small molecules, natural molecules, antibodies, or vaccines are under progress in search of effective treatment against this deadly disease (clinicaltrials.gov) [108] , [109] , [110] , [111] . Most synthetic small molecules under clinical trials are repurposed for COVID-19 which are already reported for their efficiency against other disease states ( Table 2 , Fig.…”

Novel therapeutic approaches for treatment of COVID-19

“…COVID-19 spreads fast among people and the mortality rate is controversial; however, it was less than 2% in some studies. The main manifestations of the disease include fever, dry caught, headache, shortness of breath, pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and even death [3,11,12].…”

“…Moreover, there is no licensed treatment or approved vaccine and the number of new cases and mortality multiplies daily [8]. Therefore, it is vital to develop an effective treatment strategy to control the virus spread and prevent the disease [1,11].…”

The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days

“…On December 31, 2019, the World Health Organization (WHO) China Country Office was informed of pneumonia cases of unknown etiology 1 ; on January 30, 2020, the WHO declared coronavirus disease 2019 (COVID-19) 2 a public health emergency and on March 11 a pandemic 3 . Radical public health measures, including quarantine, social distancing, school and workplace closures, and others have been implemented worldwide, affecting the lives of billions of people.…”